Benzinga
Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC) who have shown inadequate response or intolerance to ursodeoxycholic acid (UDCA), the current standard therapy. PBC is a chronic disease in which the bile ducts in the liver are slowly destroyed. The trial met its primary composite endpoint, with 51% of patients on elafibranor 80mg exhibiting a cholestasis
Benzinga